Table 3. Inter-group comparisons of patients with and without major bleeding.

		No major bleeding (n=41)				Major bleeding (n=11)					p
	n	%	Mean±SD	Median	IQR	n	%	Mean±SD	Median	IQR
Age (year)			44.0±12.1					45.8±10.3			0.61¶
Sex											0.92*
Male	14					6
Female	22					10		86.2±17.5
Mean weight (kg)			92.6±21.1								0.26§
The first 10 days of ECMO
Bivaluridin dose (mg/kg/h)				0.03	0.02-0.05				0.03	0.02-0.04	0.32§
Coagulation parameters aPTT during 10 days (sec)			49.6±8.5					47.5±7.0			0.30¶
Percentage of aPTT during 10 days
At target (45-60 sec) range (%)				63	52.3-77.3				61.0	42.1-74.7	0.46§
At <45 sec (%)				25.6	11-41				35	11.9-65.9	0.32§
At >60 sec (%)				2.6	0-21.2				0	0-10	0.24§
ACT (sec)			152.3±22.1					161.4±23.9			0.78¶
Platelet count ( 103 per μL)			100.4±55.6					107.8±60.7			0.52¶
INR			1.3±0.3					1.7±0.4			0.04¶
Fibrinogen (mg/dL)				316	201-495				368	256-481	0.20§
D-dimer (ng/mL)				4.5	2.4-8.1				7.7	4.6-18.6	0.03§
Blood product transfusions
Fresh frozen plasma (U)			7.1±2.8					8.8±3.5			0.094§
Pooled platelets (U)			0.8±1.1					1.1±1.4			0.43§
Apheresis platelets	1	2.8				3	18.7				0.081*
Cryoprecipitate	1	2.8				0	0				1.00*
Infections	26	72.2				16	100				0.019*
ECMO-circuit thrombosis	1	2.8				2	12.5				0.221*
Throughout the whole ICU stay
ICU stay (day)			62.0±32.3					69.3±32.7			0.462 ¶
ECMO duration (day)			43.7±21.8					48.3±24.1			0.53 ¶
In-hospital mortality	16	44.4				6	37.5				0.640*
SD: Standard deviation; IQR: Interquartile range; aPTT: Activated partial thromboplastin time; ACT: Activated clotting time; INR: International normalized ratio; ECMO: Extracorporeal membrane oxygen- ation; ICU: Intensive care unit; § Mann-Whitney U-test; * Chi-squared test (Fisher’s exact test); ¶ Independent samples t-test.